PRE

Prenetics Global Limited Class A Ordinary Share

PRE
Closed
$21.57
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Prenetics Global Ltd. is a health sciences company, which engages in providing consumer health products and services. The firm operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The firm's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The firm is also engaged in consumer health products by a new health and wellness brand IM8.
Country

HK

CEO

Mr. Sheng Wu Yeung

IPO date

2021

Employees

285

ISIN

KYG722451229

Key stats

Open

$21.00

Volume

348.63K

Market cap

$364.00M

Prev. close

$21.63

Impl / hst vl

-

Open interest

$0.00

$20.34

Day’s Range

$22.22

$14.00

52W Range

$23.63

Valuation

44
Valuation score
Fairly Valued
P/E
-
P/S
-
P/B
1.42
Current ratio
2.97
Debt / Equity
-
ROE
-23.96%
Gross margin
-
Income growth
-
FCF growth
-

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$31.88
The top 5 analysts forecasts that 12-month price may increase by 47.77%, with a low of $29.29 and a high of $37.80
$29.29
Low
$31.88
Avg
$37.80
High
Current price

Earnings

Q4 ‘23 revenue
$5.43M
Q4 ‘23 net income
-$19.05M
Revenue
Net income
Previous EPS
-$1.75
Estimate EPS
-$1.11
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply